Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis

Archives of Gynecology and Obstetrics

Volumn 269, Issue 3, 2004, Pages 176-180

  Milojkovic, Miodrag ^a,b   Hrgovic, Zlatko ^a,b,c   Hrgovic, Igor ^a,b   Jonat, Walter ^a,b   Maass, Nicolai ^a,b   Buković, Damir ^a,b  

^a UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^b UNIVERSITY OF KIEL   (Germany)

^c NONE   (Germany)

Author keywords

Ovarian tumors; Serum CA 125; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; CANCER STAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; OVARY TUMOR; PELVIS TUMOR; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 1642293254     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-002-0411-7     Document Type: Article

References (24)

1. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RC, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337
2. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay icing a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887
3. But I, Gorisek B (1996) Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer. Gynecol Oncol 63:166-172
4. Cruickshank DJ, Fullerton WT (1987) The clinical significance of preoperative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 94:692-695
5. De Brujin HW, van der Zee AG, Aalders JG (1997) The value of cancer antigen125 (CA 125) during treatment and follow-up of patients with ovarian cancer. (Review, 64 refs). Curr Opin Obstet Gynecol 9:8-13
6. Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M (1997) Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors. Bull Cancer 84:722-728
7. Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE (1996) Relationship of preoperative serum CA 125 to survival in epithelial ovarian carcinoma. J Reprod Med 41:140-142
8. Gonzales A, Vizoso F, Vazquez J, Ruibal A, Balibrea JL (1997) Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma. Int J Biol 12:112-117
9. Harlozinska A, Sedlaczek P, Van Valen A, Rozdolski K, Einarsson R (1997) TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res 17:4473-4478
10. Hata K, Hata T, Manbe A, Sugimura K, Kitao M (1992) A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 80:922-926
11. Hawkins RE, Roberts K, Wiltshaw E, Munday J, McCready VR (1989) The clinical correlates of serum CA 125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 60:634-637
12. Jacobs I, Oram D, Faibanks J, Turner J, Frost C, Grudzinskas JG (1990) A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 922-929
13. Jacobs IJ, Oram DH, Bast RC Jr (1992) Strategies for improving the specificity of screening for ovarian cancer with tumor associated antigens CA 125, CA 15-3, and TAG 72, 3. Obstet Gynecol 80:396-399
14. Kurjak A, Pasalic L, Marton U, Kupesic S Ilijas M, Pavlic Z (1994) Screening or early detection of ovarian cancer. Gynaecol Perinatol 3:75-81
15. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC (1987) CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69:223-227
16. Malkasian GD, Knapp RC, Lavin PT (1988) Preoperative evaluation of serum CA 125 levels in premenopausal patient with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynaecol 159:341-346
17. Masahashi T, Matsuzawa KK, Ohsawa M, Narita O, Asai T, Ishiharan M (1988) Serum CA 125 antigen levels in patients with endometriosis: changes in CA 125 levels during menstruation. Obstet Gynecol 72:328-331
18. Meier W, Stieber P, Hasholzner U, Fateh-Moghadam A (1997) Prognostic significance of CA 125 in patients with ovarian cancer and secondary debulking surgery. Anticancer Res 17:2945-2947
19. Mimica M (1993) Preoperative serum CA 125 levels in patients with ovarian tumors. Gynaecol Perinatol 2:71-74
20. Onsrud M, Shabana A, Austgulen R (1996) Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol 17:90-96
21. Paavonen J, Miettinen A, Heinonen PK, Aaran RK, Rejsala K, Aine R, Punnonen R, Laine S, Kaillioniemi OP, Lehtinen M (1989) Serum CA 125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol 96:574-579
22. Wiener Z, Thaler I, Beck D, Rottem S, Deutch M, Brandes JM (1992) Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 159-162
23. Woolas JW, Jacobs I, Xu F, Oram DH, Bast RC (1993) Serum levels of CA 125, M-CSF and OVX 1 in stage 1 and preclinical ovarian cancer. Abst Br Gynaecol Cancer Soc 2
24. Zaneta G, Valle C, Trio D, Ragoni G, Pitelli MR, Pallerino A (1993) Usefulness of color Doppler ultrasound in discriminating benign from ovarian malignant masses before surgery. Ultrasound Obstet Gynecol 3 [Suppl 1]:21